Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/209146
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Podlipnik, Sebastian | - |
dc.contributor.author | Boada, Aram | - |
dc.contributor.author | López Estebaranz, José Luis | - |
dc.contributor.author | Martín González, Manuel M. | - |
dc.contributor.author | Redondo, Pedro | - |
dc.contributor.author | Martin, Brian | - |
dc.contributor.author | Quick, Ann P. | - |
dc.contributor.author | Bailey, Christine N. | - |
dc.contributor.author | Kurley, Sarah J. | - |
dc.contributor.author | Cook, Robert W. | - |
dc.contributor.author | Puig i Sardà, Susana | - |
dc.date.accessioned | 2024-03-25T10:56:58Z | - |
dc.date.available | 2024-03-25T10:56:58Z | - |
dc.date.issued | 2022-02-19 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | http://hdl.handle.net/2445/209146 | - |
dc.description.abstract | Fifteen to forty percent of patients with localized cutaneous melanoma (CM) (stages I-II) will experience disease relapse. The 31-gene expression profile (31-GEP) uses gene expression data from the primary tumor in conjunction with clinicopathologic features to refine patient prognosis. The study's objective was to evaluate 31-GEP risk stratification for disease-free survival (DFS) in a previously published cohort with longer follow-up.Patients with stage IB-II CM (n = 86) were prospectively tested with the 31-GEP. Follow-up time increased from 2.2 to 3.9 years. Patient outcomes were compared using Kaplan-Meier and Cox regression analysis.A Class 2B result was a significant predictor of 3-year DFS (hazard ratio (HR) 8.4, p = 0.008) in univariate analysis. The 31-GEP significantly stratified patients by risk of relapse (p = 0.005). A Class 2B result was associated with a lower 3-year DFS (75.0%) than a Class 1A result (100%). The 31-GEP had a high sensitivity (77.8%) and negative predictive value (95.0%).The 31-GEP is a significant predictor of disease relapse in patients with stage IB-II melanoma and accurately stratified patients by risk of relapse. | - |
dc.format.extent | 7 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/cancers14041060 | - |
dc.relation.ispartof | Cancers, 2022, vol. 14, num. 4 | - |
dc.relation.uri | https://doi.org/10.3390/cancers14041060 | - |
dc.rights | cc by (c) Podlipnik, Sebastian et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Melanoma | - |
dc.subject.classification | Medicina personalitzada | - |
dc.subject.other | Melanoma | - |
dc.subject.other | Personalized medicine | - |
dc.title | Using a 31-Gene Expression Profile Test to Stratify Patients with Stage I-II Cutaneous Melanoma According to Recurrence Risk: Update to a Prospective, Multicenter Study | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2023-07-03T09:13:51Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 9299273 | - |
dc.identifier.pmid | 35205808 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Using a 31-Gene Expression Profile Test to Stratify Patients with Stage I–II Cutaneous Melanoma_Cancers.pdf | 633.51 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License